Building an anticancer strategy takes time and the history of anti-HER drugs development reflects the challenge that each new molecular marker faces until the approval of a targeted therapy for ...
We reviewed tumor samples of 225 patients treated uniformly in prospective trials of high-dose chemotherapy for four to nine positive axillary nodes, ≥ 10 positive nodes, or inflammatory carcinoma, ...
Young lung cancer patients have a higher incidence of targetable biomarkers, necessitating comprehensive testing for ALK fusions and EGFR mutations. Repeat biomarker testing is essential when ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results